In CML, disease relapse following TKI treatment discontinuation is attributed to quiescent LSCs, which do not rely on BCR-ABL signalling for their maintenance [24, 25]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.